抗体偶联药物治疗恶性淋巴瘤的研究进展

Research progress of antibody-drug conjugate therapy for malignant lymphoma

恶性淋巴瘤是血液系统中的一种异质性恶性肿瘤,现有治疗手段未能满足临床需求,新型治疗方案的快速兴起提高了复发或难治性恶性淋巴瘤患者的生存获益。抗体偶联药物作为一种由特异性靶向肿瘤细胞表面抗原的单克隆抗体通过化学连接子偶联小分子细胞毒性载荷而组成的新型高效抗肿瘤药物,在恶性淋巴瘤中的应用前景备受瞩目。目前已有多款治疗恶性淋巴瘤的抗体偶联药物获批,包括维布妥昔单抗、奥加伊妥珠单抗、moxetumomab pasudotox、维泊妥珠单抗和loncastuximab tesirine等。这些药物可通过靶向肿瘤细胞表面的CD30、CD22、CD79b、CD19等发挥抗肿瘤作用,疗效和安全性均较好。

Malignant lymphoma(ML)is a heterogeneous malignant tumor in the hematological system,the existing treatment methods can not meet the clinical needs,and the rapid rise of new treatment schemes has improved the survival benefits of patients with recurrent or refractory ML.Antibody-drug conjugate(ADC),as a new type of highly effective anti-tumor drug composed of monoclonal antibodies specifically targeting tumor cell surface antigens,coupled with small molecular cytotoxic loads through chemical connectors,has attracted much attention in the application prospect of malignant lymphoma.Several ADCs have been approved for the treatment of ML,including brentuximab vedotin,inotuzumab ozogamicin,moxetumomab pasudotox,polatuzumab vedotinands,loncastuximab tesirine,etc.These drugs can exert anti-tumor effects by targeting CD30,CD22,CD79b,CD19,etc.on the surface of tumor cells with good efficacy and safety.